(NASDAQ: NBTX) Nanobiotix Sa's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 86.2%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.83%.
Nanobiotix Sa's revenue in 2025 is -$7,990,000.On average, 2 Wall Street analysts forecast NBTX's revenue for 2025 to be $1,050,267,615, with the lowest NBTX revenue forecast at $345,741,744, and the highest NBTX revenue forecast at $1,754,793,487. On average, 2 Wall Street analysts forecast NBTX's revenue for 2026 to be $3,813,118,820, with the lowest NBTX revenue forecast at $3,202,260,980, and the highest NBTX revenue forecast at $4,423,976,661.
In 2027, NBTX is forecast to generate $2,544,924,825 in revenue, with the lowest revenue forecast at $2,544,924,825 and the highest revenue forecast at $2,544,924,825.